Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 16/20 | 0.53 |
| ▸ | JAK3 | P52333 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.44 |
| ▸ | PARP1 | P09874 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20164955 | 0.86 | JAK2 (0.51) | JAK2JAK3KDM4EALDH1A1HPGD | |
| SCHEMBL6646398 | 0.81 | AURKA (0.56) | KDM4EALDH1A1HPGDHSD17B10DYRK1A | |
| SCHEMBL20164967 | 0.80 | JAK2 (0.58) | JAK2JAK3KDM4EALDH1A1PARP1 | |
| SCHEMBL18132112 | 0.80 | JAK2 (0.71) | JAK2JAK3KDM4EALDH1A1 | |
| SCHEMBL18132129 | 0.80 | JAK2 (0.52) | JAK2JAK3 | |
| SCHEMBL3610664 | 0.80 | JAK2 (0.52) | JAK2JAK3 | |
| SCHEMBL3607833 | 0.76 | JAK2 (0.59) | JAK2JAK3DYRK1A | |
| SCHEMBL3612956 | 0.76 | NR4A2 (0.51) | JAK2KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL6828575 | 0.74 | KDM4E (0.63) | KDM4EALDH1A1HPGDHSD17B10DYRK1A | |
| SCHEMBL9983372 | 0.73 | DYRK1A (0.50) | JAK2KDM4EALDH1A1HPGDHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3280418-B1 | AZACARBAZOLE BTK INHIBITORS | MERCK SHARP & DOHME (US) | 2020-05-06 | — | — | EP | disclosed |
| EP-3280418-B1 | AZACARBAZOLE BTK INHIBITORS | MERCK SHARP & DOHME (US) | 2020-05-06 | — | — | EP | disclosed |
| US-20180141962-A1 | AZACARBAZOLE BTK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2018-05-24 | — | — | US | disclosed |
| US-20180141962-A1 | AZACARBAZOLE BTK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2018-05-24 | — | — | US | disclosed |
| US-20180141962-A1 | AZACARBAZOLE BTK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2018-05-24 | — | — | US | disclosed |
| WO-2016161570-A1 | AZACARBAZOLE BTK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180141962-A1 | AZACARBAZOLE BTK INHIBITORS | BTK, SYK, LYN | JAK2 6/4885JAK3 152/4885KDM4E 274/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.